Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad) Buy NVCR Stock  Free NVCR Stock Alerts

NovoCure (NVCR) Financials

NovoCure logo
$17.76 -0.39 (-2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$17.76 +0.00 (+0.03%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for NovoCure

Annual Income Statements for NovoCure

This table shows NovoCure's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -81 -112 -132 -62 -64 -7.23 20 -58 -93 -207 -169
Consolidated Net Income / (Loss)		 -81 -112 -132 -62 -64 -7.23 20 -58 -93 -207 -169
Net Income / (Loss) Continuing Operations		 -81 -112 -132 -62 -64 -7.23 20 -58 -93 -207 -169
Total Pre-Tax Income 		-80 -107 -121 -48 -46 -8.82 18 -52 -82 -192 -131
Total Operating Income		 -80 -104 -115 -39 -34 -0.91 30 -44 -90 -233 -170
Total Gross Profit		 5.45 12 37 121 168 263 388 420 423 381 468
Total Revenue		 15 33 83 177 248 351 494 535 538 509 605
Operating Revenue		 15 33 83 177 248 351 494 535 538 509 605
Total Cost of Revenue		 10 21 46 56 80 89 107 115 115 128 137
Operating Cost of Revenue		 10 21 40 56 80 89 107 115 115 128 137
Total Operating Expenses		 86 116 152 161 202 264 357 464 512 614 639
Selling, General & Admin Expense		 24 34 51 59 73 88 107 126 133 164 190
Marketing Expense		 21 39 59 64 78 97 118 137 174 227 239
Research & Development Expense		 40 44 41 38 51 79 132 201 206 223 210
Total Other Income / (Expense), net		 -0.14 -3.15 -6.15 -9.17 -12 -7.91 -12 -7.74 7.68 41 39
Interest & Investment Income		 - - - - - - -12 -7.74 7.68 41 39
Income Tax Expense		 0.38 4.43 10 13 18 -1.59 -1.71 6.28 11 15 37
Basic Earnings per Share		 ($6.46) ($3.67) ($1.54) ($0.70) ($0.69) ($0.07) $0.20 ($0.56) ($0.88) ($1.95) ($1.56)
Weighted Average Basic Shares Outstanding		 12.49M 30.40M 85.56M 88.55M 91.83M 97.24M 100.93M 103.43M 104.66M 106.39M 107.83M
Diluted Earnings per Share		 ($6.46) ($3.67) ($1.54) ($0.70) ($0.69) ($0.07) $0.18 ($0.56) ($0.88) ($1.95) ($1.56)
Weighted Average Diluted Shares Outstanding		 12.49M 30.40M 85.56M 88.55M 91.83M 97.24M 108.88M 103.43M 104.66M 106.39M 107.83M
Weighted Average Basic & Diluted Shares Outstanding		 12.49M 30.40M 85.56M 88.55M 91.83M 97.24M 102.41M 104.42M 105.46M 107.09M 109.92M

Quarterly Income Statements for NovoCure

This table shows NovoCure's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -37 -53 -57 -49 -47 -39 -33 -31 -66 -34
Consolidated Net Income / (Loss)		 -27 -37 -53 -57 -49 -47 -39 -33 -31 -66 -34
Net Income / (Loss) Continuing Operations		 -27 -37 -53 -57 -49 -47 -39 -33 -31 -66 -34
Total Pre-Tax Income 		-23 -33 -51 -54 -48 -39 -32 -23 -22 -55 -30
Total Operating Income		 -25 -43 -60 -63 -58 -52 -42 -34 -32 -63 -38
Total Gross Profit		 101 100 93 92 95 101 105 116 120 128 116
Total Revenue		 131 128 122 126 127 134 139 150 155 161 155
Operating Revenue		 131 128 122 126 127 134 139 150 155 161 155
Total Cost of Revenue		 30 29 30 34 32 33 34 35 35 33 39
Operating Cost of Revenue		 30 29 30 34 32 33 34 35 35 33 39
Total Operating Expenses		 126 143 153 155 153 153 146 149 152 191 154
Selling, General & Admin Expense		 33 38 42 41 42 39 40 38 40 72 45
Marketing Expense		 41 50 51 58 58 59 55 57 60 67 56
Research & Development Expense		 52 55 60 55 54 54 52 55 52 51 54
Total Other Income / (Expense), net		 1.19 10 9.17 8.76 10 13 9.88 11 11 8.10 7.57
Interest & Investment Income		 - - 9.17 8.76 10 13 9.88 11 11 8.10 7.57
Income Tax Expense		 3.16 4.75 1.98 3.51 1.26 8.55 7.12 11 8.99 11 4.02
Basic Earnings per Share		 ($0.25) ($0.36) ($0.50) ($0.54) ($0.46) ($0.45) ($0.36) ($0.31) ($0.28) ($0.61) ($0.31)
Weighted Average Basic Shares Outstanding		 104.88M 104.66M 105.67M 106.29M 106.77M 106.39M 107.27M 107.70M 108.25M 107.83M 110.28M
Diluted Earnings per Share		 ($0.25) ($0.36) ($0.50) ($0.54) ($0.46) ($0.45) ($0.36) ($0.31) ($0.28) ($0.61) ($0.31)
Weighted Average Diluted Shares Outstanding		 104.88M 104.66M 105.67M 106.29M 106.77M 106.39M 107.27M 107.70M 108.25M 107.83M 110.28M
Weighted Average Basic & Diluted Shares Outstanding		 104.95M 105.46M 106.21M 106.62M 106.86M 107.09M 107.61M 108.22M 108.20M 109.92M 111.49M

Annual Cash Flow Statements for NovoCure

This table details how cash moves in and out of NovoCure's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -118 62 -19 -19 62 37 67 -37 -94 127 -76
Net Cash From Operating Activities		 -74 -100 -108 -33 -1.87 27 99 83 31 -73 -26
Net Cash From Continuing Operating Activities		 -74 -100 -108 -33 -1.87 27 99 83 31 -73 -26
Net Income / (Loss) Continuing Operations		 -81 -112 -132 -62 -64 -7.23 20 -58 -93 -207 -169
Consolidated Net Income / (Loss)		 -81 -112 -132 -62 -64 -7.23 20 -58 -93 -207 -169
Depreciation Expense		 1.96 3.15 5.65 7.68 9.01 8.46 9.15 10 11 11 11
Amortization Expense		 -0.02 0.33 0.16 0.25 1.02 -2.18 3.26 3.10 -1.54 -23 -26
Non-Cash Adjustments To Reconcile Net Income		 3.46 6.82 28 27 40 52 75 104 107 146 135
Changes in Operating Assets and Liabilities, net		 1.04 1.40 -9.68 -6.76 11 -24 -8.52 24 7.03 0.15 22
Net Cash From Investing Activities		 -46 -115 13 8.63 -5.49 -52 -473 -145 -140 184 -140
Net Cash From Continuing Investing Activities		 -46 -115 13 8.63 -5.49 -52 -473 -145 -140 184 -140
Purchase of Property, Plant & Equipment		 -0.85 -4.67 -5.67 -7.37 -6.71 -10 -15 -24 -21 -27 -43
Purchase of Investments		 -138 -209 -239 -104 -254 -462 -608 -1,079 -1,298 -1,004 -875
Sale and/or Maturity of Investments		 93 104 270 120 255 421 150 958 1,179 1,215 778
Net Cash From Financing Activities		 2.15 277 75 5.17 69 62 440 26 15 16 90
Net Cash From Continuing Financing Activities		 2.15 277 75 5.17 69 62 440 26 15 16 90
Repayment of Debt		 -0.06 - - -0.08 -100 - -150 -0.03 -0.03 -0.01 -13
Issuance of Debt		 0.05 23 73 0.02 149 -0.03 558 0.00 0.00 0.00 97
Issuance of Common Equity		 2.15 254 0.62 1.54 1.84 2.47 3.37 4.55 5.22 4.42 4.15
Other Financing Activities, net		 - - 1.69 3.69 18 59 28 21 10 11 2.16
Effect of Exchange Rate Changes		 - - - - - 0.03 0.25 -0.19 -0.10 0.13 -0.17
Cash Interest Paid		 0.03 1.69 6.60 10 13 14 8.69 0.10 0.04 0.01 7.71
Cash Income Taxes Paid		 0.28 1.49 9.45 10 20 11 -3.26 3.11 5.48 14 23

Quarterly Cash Flow Statements for NovoCure

This table details how cash moves in and out of NovoCure's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -124 -128 71 -29 -0.98 86 215 -289 21 -23 -37
Net Cash From Operating Activities		 22 -3.71 -17 -23 -19 -15 -32 -1.72 10 -3.45 -36
Net Cash From Continuing Operating Activities		 22 -3.71 -17 -23 -19 -15 -32 -1.72 10 -3.45 -36
Net Income / (Loss) Continuing Operations		 -27 -37 -53 -57 -49 -47 -39 -33 -31 -66 -34
Consolidated Net Income / (Loss)		 -27 -37 -53 -57 -49 -47 -39 -33 -31 -66 -34
Depreciation Expense		 2.66 2.70 2.72 2.72 2.80 2.72 2.82 2.86 2.46 3.10 3.33
Amortization Expense		 0.23 -3.28 -4.06 -5.08 -6.69 -7.26 -5.38 -6.85 -6.74 -6.67 -6.65
Non-Cash Adjustments To Reconcile Net Income		 26 28 54 41 30 21 32 22 37 45 23
Changes in Operating Assets and Liabilities, net		 20 5.71 -16 -3.70 3.56 16 -22 14 8.50 21 -21
Net Cash From Investing Activities		 -150 -128 82 -14 17 99 246 -374 10 -22 -6.47
Net Cash From Continuing Investing Activities		 -150 -128 82 -14 17 99 246 -374 10 -22 -6.47
Purchase of Property, Plant & Equipment		 -5.70 -6.43 -6.09 -6.93 -7.25 -6.82 -12 -11 -11 -8.94 -11
Purchase of Investments		 -503 -226 -238 -322 -251 -193 0.00 -523 -169 -183 -116
Sale and/or Maturity of Investments		 359 105 326 315 276 299 258 160 190 170 120
Net Cash From Financing Activities		 4.20 3.41 5.20 7.50 1.17 1.91 0.21 87 0.10 2.69 5.25
Net Cash From Continuing Financing Activities		 4.20 3.41 5.20 7.50 1.17 1.91 0.21 87 0.10 2.69 5.25
Repayment of Debt		 -0.01 -0.01 -0.01 -0.00 - - 0.00 -13 - - 0.00
Issuance of Debt		 - - - - - - - - - - 0.00
Issuance of Common Equity		 - 2.47 0.00 2.88 - 1.53 0.00 2.19 - 1.96 0.00
Other Financing Activities, net		 4.21 0.95 5.21 4.62 1.17 0.38 0.21 1.12 0.10 0.72 5.25
Effect of Exchange Rate Changes		 -0.11 0.16 0.04 -0.01 -0.10 0.20 -0.06 -0.08 0.09 -0.13 0.23
Cash Interest Paid		 0.00 0.04 0.00 - - 0.01 0.00 1.97 2.96 2.78 2.65
Cash Income Taxes Paid		 0.91 1.55 1.71 5.83 1.20 4.92 2.91 7.50 6.64 6.41 4.97

Annual Balance Sheets for NovoCure

This table presents NovoCure's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 118 307 282 265 340 479 1,052 1,139 1,192 1,146 1,241
Total Current Assets		 112 294 262 245 321 440 999 1,074 1,112 1,034 1,107
Cash & Equivalents		 58 119 100 79 141 177 235 209 115 241 164
Restricted Cash		 0.06 0.09 0.27 2.13 2.13 2.10 11 0.81 0.51 1.74 2.33
Short-Term Investments		 45 150 120 105 105 149 608 729 854 670 796
Accounts Receivable		 - 0.00 6.34 30 37 59 97 94 86 61 74
Inventories, net		 3.45 14 26 22 23 24 27 24 29 38 35
Other Current Assets		 5.71 11 10 8.11 14 29 21 17 26 23 35
Plant, Property, & Equipment, net		 3.73 6.55 9.81 9.03 8.44 9.34 11 23 33 51 78
Total Noncurrent Assets		 2.31 6.88 10 11 9.98 30 41 43 47 60 57
Other Noncurrent Operating Assets		 2.31 6.88 10 11 9.98 30 41 43 47 60 57
Total Liabilities & Shareholders' Equity		 118 307 282 265 340 479 1,052 1,139 1,192 1,146 1,241
Total Liabilities		 20 57 140 152 228 262 575 729 750 784 881
Total Current Liabilities		 18 29 37 50 65 86 114 143 159 179 756
Short-Term Debt		 - - - - - - - - - 0.00 558
Accounts Payable		 18 29 37 50 65 86 54 73 85 94 105
Accrued Expenses		 - - - - - - 60 70 74 85 93
Total Noncurrent Liabilities		 2.33 28 103 102 163 175 462 586 592 605 124
Long-Term Debt		 0.00 23 96 97 149 149 430 562 566 569 97
Noncurrent Employee Benefit Liabilities		 0.25 2.06 2.59 2.45 2.68 3.75 5.17 4.54 4.40 8.26 6.94
Other Noncurrent Operating Liabilities		 2.09 2.74 4.03 1.74 1.09 0.22 0.34 0.17 19 27 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 98 251 142 114 112 218 477 410 441 362 360
Total Preferred & Common Equity		 98 251 142 114 112 218 477 410 441 362 360
Total Common Equity		 98 251 142 114 112 218 477 410 441 362 360
Common Stock		 374 640 664 697 757 871 1,111 1,100 1,222 1,353 1,520
Retained Earnings		 -277 -388 -520 -582 -644 -651 -631 -686 -778 -986 -1,154
Accumulated Other Comprehensive Income / (Loss)		 0.00 -1.51 -1.88 -1.34 -1.40 -2.77 -3.83 -3.17 -2.43 -5.47 -5.50

Quarterly Balance Sheets for NovoCure

This table presents NovoCure's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 1,174 1,174 1,159 1,146 1,121 1,212 1,222 1,249
Total Current Assets		 1,102 1,089 1,065 1,048 1,003 1,093 1,095 1,089
Cash & Equivalents		 244 186 157 155 454 165 185 127
Restricted Cash		 0.23 0.68 0.52 1.65 3.60 3.65 3.78 2.15
Short-Term Investments		 727 772 784 766 416 786 774 802
Accounts Receivable		 88 75 71 65 65 65 67 85
Inventories, net		 27 32 33 37 42 40 39 39
Other Current Assets		 17 - 20 23 21 33 25 34
Plant, Property, & Equipment, net		 30 36 41 46 59 66 73 80
Total Noncurrent Assets		 42 49 52 53 60 53 53 80
Other Noncurrent Operating Assets		 42 49 52 53 60 53 53 80
Total Liabilities & Shareholders' Equity		 1,174 1,174 1,159 1,146 1,121 1,212 1,222 1,249
Total Liabilities		 729 742 743 753 762 850 861 887
Total Current Liabilities		 141 149 150 157 160 169 735 743
Short-Term Debt		 - - - - - - 557 559
Accounts Payable		 77 81 83 80 84 90 91 95
Accrued Expenses		 64 67 68 77 76 79 86 89
Total Noncurrent Liabilities		 588 593 593 595 602 681 126 144
Long-Term Debt		 565 566 567 568 570 653 97 97
Noncurrent Employee Benefit Liabilities		 4.09 5.14 4.84 5.37 6.57 6.02 7.89 5.77
Other Noncurrent Operating Liabilities		 15 20 20 22 26 22 21 40
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 445 432 416 394 359 362 361 362
Total Preferred & Common Equity		 445 432 416 394 359 362 361 362
Total Common Equity		 445 432 416 394 359 362 361 362
Common Stock		 1,189 1,266 1,307 1,334 1,388 1,423 1,454 1,555
Retained Earnings		 -741 -832 -889 -938 -1,024 -1,058 -1,088 -1,188
Accumulated Other Comprehensive Income / (Loss)		 -2.31 -2.69 -1.98 -1.99 -4.15 -3.52 -5.38 -4.20

Annual Metrics and Ratios for NovoCure

This table displays calculated financial ratios and metrics derived from NovoCure's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 49.53% 113.60% 150.52% 113.57% 40.13% 41.62% 40.72% 8.23% 0.53% -5.30% 18.82%
EBITDA Growth		 -35.29% -28.51% -8.95% 71.33% 24.70% 122.71% 697.23% -172.37% -159.63% -204.58% 24.52%
EBIT Growth		 -24.35% -29.74% -10.89% 65.90% 14.38% 97.29% 3,426.15% -245.83% -101.93% -160.12% 26.78%
NOPAT Growth		 -24.35% -29.74% -10.89% 65.90% 14.38% 97.29% 5,299.45% -193.29% -101.93% -160.12% 26.78%
Net Income Growth		 -4.28% -38.30% -18.16% 53.23% -3.08% 88.62% 373.97% -394.58% -58.58% -123.75% 18.55%
EPS Growth		 4.01% 43.19% 58.04% 54.55% 1.43% 89.86% 357.14% -411.11% -57.14% -121.59% 20.00%
Operating Cash Flow Growth		 -40.84% -34.53% -7.72% 69.20% 94.37% 1,527.35% 272.46% -16.53% -62.80% -338.20% 64.04%
Free Cash Flow Firm Growth		 0.00% -59.81% -15.84% 63.87% 66.16% -246.87% 149.10% -158.55% -350.72% -178.14% -5.93%
Invested Capital Growth		 0.00% 191.83% 323.85% 36.38% -46.94% 293.41% 25.35% -29.18% -22.15% -48.41% 181.87%
Revenue Q/Q Growth		 0.00% 0.00% 27.46% 15.25% 6.90% 9.19% 9.95% -1.97% -0.88% 1.06% 4.76%
EBITDA Q/Q Growth		 0.00% 0.00% 10.76% 30.58% -24.23% 244.16% 61.62% -516.36% -41.56% -5.47% -6.09%
EBIT Q/Q Growth		 0.00% 0.00% 9.94% 25.37% -14.09% 90.61% 64.67% -401.33% -27.99% -3.90% -7.29%
NOPAT Q/Q Growth		 0.00% 0.00% 9.94% 25.37% -14.09% 90.61% -27.69% -401.33% -27.99% -3.90% -7.29%
Net Income Q/Q Growth		 0.00% 0.00% 7.55% 15.40% -7.96% 73.34% 3.43% -116.31% -13.28% -4.96% -12.58%
EPS Q/Q Growth		 0.00% 0.00% -222.22% 15.66% -6.15% 75.00% -10.00% -100.00% -14.29% -4.84% -11.43%
Operating Cash Flow Q/Q Growth		 0.00% -9.31% 10.33% 24.63% 91.36% -27.01% 88.39% -32.07% -37.04% -17.37% 29.64%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 20.81% 61.12% -1,752.54% 3,227.03% -145.33% -7.49% 7.00% -24.02%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.43% 1.68% -60.56% 112.54% -6.99% 18.26% -7.04% -51.12% 3.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 35.21% 37.71% 44.16% 68.59% 67.73% 74.78% 78.46% 78.53% 78.64% 74.81% 77.33%
EBITDA Margin		 -504.93% -303.79% -132.12% -17.74% -9.53% 1.53% 8.66% -5.79% -14.96% -48.10% -30.55%
Operating Margin		 -517.47% -314.31% -139.12% -22.22% -13.57% -0.26% 6.15% -8.29% -16.64% -45.72% -28.17%
EBIT Margin		 -517.47% -314.31% -139.12% -22.22% -13.57% -0.26% 6.15% -8.29% -16.64% -45.72% -28.17%
Profit (Net Income) Margin		 -520.87% -337.24% -159.06% -34.83% -25.62% -2.06% 4.01% -10.91% -17.20% -40.65% -27.86%
Tax Burden Percent		 100.48% 104.14% 108.55% 127.15% 138.35% 81.94% 109.42% 112.05% 113.06% 107.98% 128.56%
Interest Burden Percent		 100.18% 103.03% 105.33% 123.31% 136.44% 965.43% 59.54% 117.46% 91.42% 82.34% 76.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.42% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -699.47% -124.73% -120.92% -1.92% 55.53% -54.52% -149.30% -585.26% -329.70%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -671.84% -92.49% -78.12% 3.09% 60.21% -47.45% -141.52% -573.48% -314.54%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 632.40% 76.54% 64.63% -2.46% -49.82% 41.36% 127.57% 533.73% 283.03%
Return on Equity (ROE)		 -82.43% -64.00% -67.07% -48.19% -56.29% -4.38% 5.71% -13.16% -21.73% -51.52% -46.67%
Cash Return on Invested Capital (CROIC)		 0.00% -1,861.13% -823.11% -155.51% -59.60% -120.85% 33.03% -20.35% -124.39% -521.40% -424.95%
Operating Return on Assets (OROA)		 -68.00% -48.91% -39.13% -14.37% -11.13% -0.22% 3.97% -4.05% -7.68% -19.92% -14.29%
Return on Assets (ROA)		 -68.45% -52.48% -44.74% -22.53% -21.01% -1.77% 2.59% -5.33% -7.94% -17.71% -14.13%
Return on Common Equity (ROCE)		 -82.43% -64.00% -67.07% -48.19% -56.29% -4.38% 5.71% -13.16% -21.73% -51.52% -46.67%
Return on Equity Simple (ROE_SIMPLE)		 -82.43% -44.49% -92.62% -54.30% -56.62% -3.32% 4.16% -14.21% -20.97% -57.12% -46.82%
Net Operating Profit after Tax (NOPAT)		 -56 -73 -81 -28 -24 -0.64 33 -31 -63 -163 -119
NOPAT Margin		 -362.23% -220.02% -97.39% -15.55% -9.50% -0.18% 6.73% -5.80% -11.65% -32.00% -19.72%
Net Nonoperating Expense Percent (NNEP)		 -47.87% -22.22% -27.63% -32.24% -42.81% -5.00% -4.69% -7.07% -7.78% -11.77% -15.16%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -6.23% -17.50% -11.75%
Cost of Revenue to Revenue		 64.79% 62.29% 55.84% 31.41% 32.27% 25.22% 21.54% 21.47% 21.36% 25.19% 22.67%
SG&A Expenses to Revenue		 155.27% 102.35% 61.54% 33.39% 29.61% 25.03% 21.73% 23.57% 24.68% 32.21% 31.37%
R&D to Revenue		 260.69% 132.22% 50.03% 21.52% 20.39% 22.49% 26.70% 37.62% 38.32% 43.79% 34.64%
Operating Expenses to Revenue		 552.68% 352.02% 183.29% 90.80% 81.31% 75.04% 72.31% 86.82% 95.29% 120.53% 105.50%
Earnings before Interest and Taxes (EBIT)		 -80 -104 -115 -39 -34 -0.91 30 -44 -90 -233 -170
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -101 -110 -31 -24 5.37 43 -31 -80 -245 -185
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 7.45 4.79 15.90 27.74 38.29 36.97 18.99 17.45 4.40 8.95
Price to Tangible Book Value (P/TBV)		 0.00 7.45 4.79 15.90 27.74 38.29 36.97 18.99 17.45 4.40 8.95
Price to Revenue (P/Rev)		 0.00 56.51 8.22 10.20 12.55 23.74 35.63 14.57 14.31 3.13 5.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 889.29 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.11% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 368.43 29.86 67.42 223.11 153.76 258.15 157.45 198.49 66.03 54.60
Enterprise Value to Revenue (EV/Rev)		 0.00 49.06 6.73 9.70 12.16 23.27 34.80 13.89 13.56 2.46 4.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 1,522.43 401.89 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 565.94 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 517.20 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 307.12 173.53 89.80 236.90 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 869.56 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.09 0.68 0.86 1.33 0.75 0.93 1.40 1.28 1.57 1.82
Long-Term Debt to Equity		 0.00 0.09 0.68 0.86 1.33 0.75 0.93 1.40 1.28 1.57 0.27
Financial Leverage		 -1.05 -1.00 -0.94 -0.83 -0.83 -0.80 -0.83 -0.87 -0.90 -0.93 -0.90
Leverage Ratio		 1.20 1.22 1.50 2.14 2.68 2.48 2.21 2.47 2.74 2.91 3.30
Compound Leverage Factor		 1.21 1.26 1.58 2.64 3.66 23.96 1.31 2.90 2.50 2.40 2.54
Debt to Total Capital		 0.00% 8.43% 40.34% 46.15% 57.08% 42.89% 48.24% 58.36% 56.18% 61.08% 64.54%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.96%
Long-Term Debt to Total Capital		 0.00% 8.43% 40.34% 46.15% 57.08% 42.89% 48.24% 58.36% 56.18% 61.08% 9.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 91.57% 59.66% 53.85% 42.92% 57.11% 51.76% 41.64% 43.82% 38.92% 35.46%
Debt to EBITDA		 0.00 -0.23 -0.88 -3.10 -6.31 30.46 10.38 -18.57 -7.03 -2.32 -3.54
Net Debt to EBITDA		 0.00 2.45 1.13 2.81 4.18 -30.66 -9.57 11.73 5.03 1.40 1.66
Long-Term Debt to EBITDA		 0.00 -0.23 -0.88 -3.10 -6.31 30.46 10.38 -18.57 -7.03 -2.32 -0.53
Debt to NOPAT		 0.00 -0.32 -1.19 -3.54 -6.33 -255.65 13.35 -18.54 -9.02 -3.49 -5.49
Net Debt to NOPAT		 0.00 3.38 1.53 3.20 4.19 257.30 -12.32 11.71 6.45 2.11 2.57
Long-Term Debt to NOPAT		 0.00 -0.32 -1.19 -3.54 -6.33 -255.65 13.35 -18.54 -9.02 -3.49 -0.82
Altman Z-Score		 0.00 18.11 0.25 5.13 6.87 18.84 19.10 6.89 6.40 0.69 1.27
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.33 10.27 7.10 4.88 4.98 5.10 8.80 7.53 7.00 5.78 1.46
Quick Ratio		 5.81 9.41 6.13 4.24 4.37 4.46 8.27 7.23 6.65 5.43 1.37
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -51 -82 -95 -34 -12 -40 20 -12 -52 -145 -154
Operating Cash Flow to CapEx		 -8,744.88% -2,140.22% -1,896.56% -449.82% -27.79% 253.89% 662.40% 342.39% 144.15% -270.68% -61.53%
Free Cash Flow to Firm to Interest Expense		 -356.33 -26.02 -15.45 -3.74 -0.95 -5.09 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -515.58 -31.70 -17.50 -3.61 -0.15 3.37 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -521.48 -33.18 -18.43 -4.42 -0.70 2.04 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.16 0.28 0.65 0.82 0.86 0.65 0.49 0.46 0.44 0.51
Accounts Receivable Turnover		 0.00 0.00 0.00 9.86 7.51 7.37 6.36 5.62 5.98 6.91 8.94
Inventory Turnover		 2.91 2.42 2.36 2.34 3.59 3.83 4.17 4.43 4.27 3.80 3.75
Fixed Asset Turnover		 4.15 6.43 10.13 18.79 28.39 39.51 47.68 31.39 19.43 12.10 9.37
Accounts Payable Turnover		 0.57 0.89 1.41 1.28 1.40 1.17 1.52 1.82 1.46 1.43 1.38
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 37.02 48.62 49.55 57.43 64.90 61.02 52.84 40.84
Days Inventory Outstanding (DIO)		 125.33 150.89 154.35 156.13 101.64 95.27 87.60 82.37 85.48 96.07 97.43
Days Payable Outstanding (DPO)		 642.61 409.95 258.32 285.79 261.64 310.75 239.83 200.56 250.71 255.49 265.38
Cash Conversion Cycle (CCC)		 -517.28 -259.06 -103.97 -92.65 -111.39 -165.93 -94.80 -53.29 -104.21 -106.58 -127.10
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.80 4.41 19 25 14 53 67 47 37 19 53
Invested Capital Turnover		 -6.46 -168.81 7.18 8.02 12.73 10.54 8.25 9.40 12.81 18.29 16.72
Increase / (Decrease) in Invested Capital		 -4.80 9.20 14 6.79 -12 40 13 -19 -10 -18 34
Enterprise Value (EV)		 0.00 1,623 558 1,717 3,015 8,175 17,205 7,431 7,294 1,252 2,918
Market Capitalization		 0.00 1,870 681 1,805 3,114 8,340 17,615 7,795 7,698 1,595 3,224
Book Value per Share		 $7.84 $3.00 $1.64 $1.27 $1.21 $2.20 $4.68 $3.95 $4.20 $3.39 $3.33
Tangible Book Value per Share		 $7.84 $3.00 $1.64 $1.27 $1.21 $2.20 $4.68 $3.95 $4.20 $3.39 $3.33
Total Capital		 98 274 239 211 262 381 921 986 1,007 931 1,016
Total Debt		 0.00 23 96 97 149 164 444 575 566 569 655
Total Long-Term Debt		 0.00 23 96 97 149 164 444 575 566 569 97
Net Debt		 -103 -246 -124 -88 -99 -165 -410 -363 -404 -344 -307
Capital Expenditures (CapEx)		 0.85 4.67 5.67 7.37 6.71 10 15 24 21 27 43
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.51 -4.23 5.09 9.50 8.80 25 32 -7.58 -17 -57 -54
Debt-free Net Working Capital (DFNWC)		 94 265 225 195 257 354 886 931 953 855 908
Net Working Capital (NWC)		 94 265 225 195 257 354 886 931 953 855 350
Net Nonoperating Expense (NNE)		 25 39 51 34 40 6.59 13 27 30 44 49
Net Nonoperating Obligations (NNO)		 -103 -246 -124 -88 -99 -165 -410 -363 -404 -344 -307
Total Depreciation and Amortization (D&A)		 1.94 3.48 5.81 7.93 10 6.28 12 13 9.09 -12 -14
Debt-free, Cash-free Net Working Capital to Revenue		 -54.95% -12.80% 6.14% 5.36% 3.55% 7.24% 6.42% -1.42% -3.19% -11.20% -8.90%
Debt-free Net Working Capital to Revenue		 607.88% 801.76% 271.44% 110.11% 103.52% 100.66% 179.18% 173.99% 177.14% 167.92% 150.09%
Net Working Capital to Revenue		 607.88% 801.76% 271.44% 110.11% 103.52% 100.66% 179.18% 173.99% 177.14% 167.92% 57.86%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($6.46) ($3.67) ($1.54) ($0.70) ($0.69) ($0.07) $0.20 ($0.56) ($0.88) ($1.95) ($1.56)
Adjusted Weighted Average Basic Shares Outstanding		 12.49M 84.43M 87.07M 89.88M 94.99M 99.64M 100.93M 103.43M 104.66M 106.39M 107.83M
Adjusted Diluted Earnings per Share		 ($6.46) ($3.67) ($1.54) ($0.70) ($0.69) ($0.07) $0.18 ($0.56) ($0.88) ($1.95) ($1.56)
Adjusted Weighted Average Diluted Shares Outstanding		 12.49M 84.43M 87.07M 89.88M 94.99M 99.64M 108.88M 103.43M 104.66M 106.39M 107.83M
Adjusted Basic & Diluted Earnings per Share		 ($6.46) ($3.67) ($1.54) ($0.70) ($0.69) ($0.07) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.49M 30.40M 85.56M 88.55M 91.83M 97.24M 102.41M 104.42M 105.46M 107.09M 109.92M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -73 -81 -28 -24 -0.64 21 -31 -63 -163 -119
Normalized NOPAT Margin		 -362.23% -220.02% -97.39% -15.55% -9.50% -0.18% 4.30% -5.80% -11.65% -32.00% -19.72%
Pre Tax Income Margin		 -518.40% -323.83% -146.54% -27.40% -18.52% -2.51% 3.66% -9.73% -15.22% -37.64% -21.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -556.64 -33.00 -18.76 -4.29 -2.74 -0.12 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -389.65 -23.10 -13.13 -3.00 -1.92 -0.08 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -562.53 -34.49 -19.68 -5.09 -3.29 -1.44 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -395.54 -24.58 -14.05 -3.81 -2.47 -1.41 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for NovoCure

This table displays calculated financial ratios and metrics derived from NovoCure's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.95% -3.59% -11.17% -10.52% -2.81% 4.17% 13.36% 19.28% 21.81% 20.54% 11.91%
EBITDA Growth		 -331.53% -118.41% -2,575.20% -268.41% -186.08% -29.15% 28.41% 42.20% 41.46% -18.87% 6.56%
EBIT Growth		 -187.78% -83.68% -7,375.06% -196.57% -136.66% -20.33% 31.09% 46.41% 44.90% -22.41% 8.80%
NOPAT Growth		 -187.78% -83.68% -7,375.06% -196.57% -136.66% -20.33% 31.09% 46.41% 44.90% -22.41% 8.80%
Net Income Growth		 -102.50% -40.99% -1,041.83% -139.16% -86.20% -26.21% 26.95% 41.87% 38.22% -40.02% 11.46%
EPS Growth		 -92.31% -44.00% -1,150.00% -134.78% -84.00% -25.00% 28.00% 42.59% 39.13% -35.56% 13.89%
Operating Cash Flow Growth		 -8.11% -125.74% -353.68% -244.25% -186.15% -292.72% -88.76% 92.44% 153.72% 76.29% -12.96%
Free Cash Flow Firm Growth		 -165.39% -739.35% -56.00% -22.81% -137.70% 6.20% -174.82% -45.61% 11.92% -327.89% -30.91%
Invested Capital Growth		 -0.96% -22.15% -39.50% -26.22% -1.86% -48.41% 38.99% 45.50% 32.99% 181.87% 57.61%
Revenue Q/Q Growth		 -7.01% -1.96% -4.86% 3.17% 1.01% 5.08% 3.53% 8.56% 3.15% 3.98% -3.89%
EBITDA Q/Q Growth		 -23.07% -100.55% -41.38% -5.57% 4.43% 9.46% 21.63% 14.77% 3.21% -83.86% 38.40%
EBIT Q/Q Growth		 -16.49% -74.63% -40.19% -4.00% 7.05% 11.21% 19.72% 19.12% 4.43% -97.26% 40.19%
NOPAT Q/Q Growth		 -16.49% -74.63% -40.19% -4.00% 7.05% 11.21% 19.72% 19.12% 4.43% -97.26% 40.19%
Net Income Q/Q Growth		 -10.70% -40.36% -42.24% -8.21% 13.82% 4.86% 17.67% 13.89% 8.40% -115.64% 47.94%
EPS Q/Q Growth		 -8.70% -44.00% -38.89% -8.00% 14.81% 2.17% 20.00% 13.89% 9.68% -117.86% 49.18%
Operating Cash Flow Q/Q Growth		 42.24% -116.53% -351.23% -35.93% 15.05% 24.62% -116.88% 94.55% 703.26% -133.26% -933.47%
Free Cash Flow Firm Q/Q Growth		 28.95% -16.55% 17.39% -79.52% -37.52% 54.00% -142.01% 4.88% 16.82% -123.45% 25.96%
Invested Capital Q/Q Growth		 -29.73% -7.04% 8.20% 4.38% -6.53% -51.12% 191.47% 9.28% -14.57% 3.59% 62.98%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.29% 77.51% 75.76% 73.01% 74.79% 75.67% 75.68% 76.95% 77.19% 79.25% 75.15%
EBITDA Margin		 -16.58% -33.92% -50.40% -51.58% -48.80% -42.05% -31.83% -24.99% -23.45% -41.47% -26.58%
Operating Margin		 -18.79% -33.46% -49.31% -49.71% -45.75% -38.66% -29.98% -22.33% -20.69% -39.25% -24.43%
EBIT Margin		 -18.79% -33.46% -49.31% -49.71% -45.75% -38.66% -29.98% -22.33% -20.69% -39.25% -24.43%
Profit (Net Income) Margin		 -20.29% -29.05% -43.43% -45.55% -38.87% -35.19% -27.99% -22.20% -19.71% -40.88% -22.14%
Tax Burden Percent		 113.49% 114.57% 103.88% 106.52% 102.62% 122.18% 122.50% 146.84% 141.63% 119.41% 113.28%
Interest Burden Percent		 95.15% 75.76% 84.78% 86.03% 82.79% 74.51% 76.21% 67.69% 67.26% 87.21% 80.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -179.66% -300.17% -341.97% -361.42% -412.14% -494.84% -232.18% -168.77% -185.18% -459.41% -149.37%
ROIC Less NNEP Spread (ROIC-NNEP)		 -177.26% -298.29% -339.11% -357.85% -409.85% -491.93% -229.39% -165.85% -182.74% -452.77% -146.67%
Return on Net Nonoperating Assets (RNNOA)		 160.86% 268.89% 297.90% 317.05% 371.60% 457.83% 201.85% 144.11% 160.85% 407.41% 117.73%
Return on Equity (ROE)		 -18.80% -31.28% -44.06% -44.37% -40.54% -37.01% -30.32% -24.66% -24.33% -52.00% -31.65%
Cash Return on Invested Capital (CROIC)		 -122.30% -124.39% -148.50% -242.65% -398.78% -521.40% -348.14% -291.35% -274.48% -424.95% -208.81%
Operating Return on Assets (OROA)		 -8.89% -15.44% -22.17% -21.74% -19.87% -16.84% -13.73% -10.36% -10.10% -19.91% -12.82%
Return on Assets (ROA)		 -9.59% -13.40% -19.52% -19.92% -16.88% -15.33% -12.82% -10.30% -9.62% -20.73% -11.62%
Return on Common Equity (ROCE)		 -18.80% -31.28% -44.06% -44.37% -40.54% -37.01% -30.32% -24.66% -24.33% -52.00% -31.65%
Return on Equity Simple (ROE_SIMPLE)		 -18.34% 0.00% -32.62% -41.94% -50.11% 0.00% -53.64% -46.63% -41.52% 0.00% -45.36%
Net Operating Profit after Tax (NOPAT)		 -17 -30 -42 -44 -41 -36 -29 -24 -22 -44 -27
NOPAT Margin		 -13.15% -23.43% -34.52% -34.80% -32.02% -27.06% -20.98% -15.63% -14.48% -27.48% -17.10%
Net Nonoperating Expense Percent (NNEP)		 -2.40% -1.88% -2.86% -3.57% -2.29% -2.91% -2.78% -2.92% -2.44% -6.65% -2.70%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.99% - - - -3.89% - - - -4.36% -2.60%
Cost of Revenue to Revenue		 22.71% 22.49% 24.24% 26.99% 25.21% 24.33% 24.32% 23.05% 22.81% 20.75% 24.85%
SG&A Expenses to Revenue		 24.82% 29.64% 34.33% 32.35% 32.90% 29.49% 28.54% 25.08% 25.86% 44.95% 28.88%
R&D to Revenue		 39.66% 42.69% 48.86% 43.97% 42.12% 40.59% 37.25% 36.55% 33.45% 31.76% 34.70%
Operating Expenses to Revenue		 96.08% 110.97% 125.07% 122.72% 120.54% 114.32% 105.65% 99.29% 97.89% 118.50% 99.58%
Earnings before Interest and Taxes (EBIT)		 -25 -43 -60 -63 -58 -52 -42 -34 -32 -63 -38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -44 -62 -65 -62 -56 -44 -38 -36 -67 -41
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 17.87 17.45 14.68 10.60 4.37 4.40 4.65 5.10 4.69 8.95 5.41
Price to Tangible Book Value (P/TBV)		 17.87 17.45 14.68 10.60 4.37 4.40 4.65 5.10 4.69 8.95 5.41
Price to Revenue (P/Rev)		 14.67 14.31 12.14 8.68 3.42 3.13 3.18 3.35 2.93 5.33 3.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 191.06 198.49 149.64 97.19 35.24 66.03 24.72 25.54 26.79 54.60 19.33
Enterprise Value to Revenue (EV/Rev)		 13.92 13.56 11.39 7.95 2.71 2.46 2.60 2.80 2.39 4.82 2.71
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 154.44 236.90 335.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.27 1.28 1.31 1.36 1.44 1.57 1.59 1.81 1.81 1.82 1.81
Long-Term Debt to Equity		 1.27 1.28 1.31 1.36 1.44 1.57 1.59 1.81 0.27 0.27 0.27
Financial Leverage		 -0.91 -0.90 -0.88 -0.89 -0.91 -0.93 -0.88 -0.87 -0.88 -0.90 -0.80
Leverage Ratio		 2.67 2.74 2.68 2.71 2.77 2.91 2.90 3.05 3.14 3.30 3.29
Compound Leverage Factor		 2.54 2.07 2.27 2.33 2.29 2.17 2.21 2.06 2.11 2.88 2.63
Debt to Total Capital		 55.90% 56.18% 56.72% 57.71% 59.06% 61.08% 61.32% 64.37% 64.46% 64.54% 64.46%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.90% 54.96% 54.89%
Long-Term Debt to Total Capital		 55.90% 56.18% 56.72% 57.71% 59.06% 61.08% 61.32% 64.37% 9.57% 9.58% 9.57%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 44.10% 43.82% 43.28% 42.29% 40.94% 38.92% 38.68% 35.63% 35.54% 35.46% 35.54%
Debt to EBITDA		 -9.94 -7.03 -3.92 -2.96 -2.45 -2.32 -2.50 -3.27 -3.76 -3.54 -3.61
Net Debt to EBITDA		 7.14 5.03 2.72 1.95 1.53 1.40 1.34 1.51 1.77 1.66 1.51
Long-Term Debt to EBITDA		 -9.94 -7.03 -3.92 -2.96 -2.45 -2.32 -2.50 -3.27 -0.56 -0.53 -0.54
Debt to NOPAT		 -11.53 -9.02 -5.43 -4.25 -3.62 -3.49 -3.80 -5.04 -5.88 -5.49 -5.62
Net Debt to NOPAT		 8.29 6.45 3.76 2.81 2.26 2.11 2.03 2.33 2.78 2.57 2.35
Long-Term Debt to NOPAT		 -11.53 -9.02 -5.43 -4.25 -3.62 -3.49 -3.80 -5.04 -0.87 -0.82 -0.83
Altman Z-Score		 7.04 6.53 5.37 3.69 1.43 1.21 1.28 1.36 0.67 1.55 0.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.81 7.00 7.32 7.10 6.67 5.78 6.26 6.46 1.49 1.46 1.47
Quick Ratio		 7.50 6.65 6.94 6.74 6.28 5.43 5.84 6.00 1.40 1.37 1.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -20 -16 -29 -40 -18 -45 -42 -35 -79 -58
Operating Cash Flow to CapEx		 393.13% -57.64% -274.75% -328.05% -266.29% -213.43% -267.94% -15.03% 97.13% -38.59% -336.11%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.47 0.46 0.45 0.44 0.43 0.44 0.46 0.46 0.49 0.51 0.52
Accounts Receivable Turnover		 5.97 5.98 5.94 6.02 6.60 6.91 7.51 8.11 8.74 8.94 8.31
Inventory Turnover		 4.68 4.27 3.84 3.91 3.92 3.80 3.57 3.62 3.59 3.75 3.47
Fixed Asset Turnover		 26.19 19.43 16.98 14.99 13.38 12.10 11.02 10.22 9.73 9.37 8.98
Accounts Payable Turnover		 1.69 1.46 1.55 1.51 1.59 1.43 1.60 1.54 1.59 1.38 1.58
Days Sales Outstanding (DSO)		 61.10 61.02 61.41 60.59 55.29 52.84 48.58 45.03 41.76 40.84 43.91
Days Inventory Outstanding (DIO)		 78.00 85.48 95.05 93.37 93.14 96.07 102.19 100.81 101.65 97.43 105.20
Days Payable Outstanding (DPO)		 216.21 250.71 235.49 242.47 229.49 255.49 228.60 237.00 228.99 265.38 230.55
Cash Conversion Cycle (CCC)		 -77.11 -104.21 -79.04 -88.51 -81.05 -106.58 -77.82 -91.16 -85.58 -127.10 -81.44
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 40 37 40 42 39 19 55 60 52 53 87
Invested Capital Turnover		 13.66 12.81 9.91 10.39 12.87 18.29 11.06 10.80 12.78 16.72 8.73
Increase / (Decrease) in Invested Capital		 -0.39 -10 -26 -15 -0.74 -18 16 19 13 34 32
Enterprise Value (EV)		 7,552 7,294 5,950 4,034 1,367 1,252 1,366 1,542 1,382 2,918 1,684
Market Capitalization		 7,958 7,698 6,342 4,408 1,722 1,595 1,670 1,843 1,691 3,224 1,959
Book Value per Share		 $4.25 $4.20 $4.10 $3.91 $3.69 $3.39 $3.35 $3.36 $3.33 $3.33 $3.29
Tangible Book Value per Share		 $4.25 $4.20 $4.10 $3.91 $3.69 $3.39 $3.35 $3.36 $3.33 $3.33 $3.29
Total Capital		 1,010 1,007 998 983 962 931 929 1,015 1,015 1,016 1,018
Total Debt		 565 566 566 567 568 569 570 653 654 655 656
Total Long-Term Debt		 565 566 566 567 568 569 570 653 97 97 97
Net Debt		 -406 -404 -392 -374 -355 -344 -304 -301 -309 -307 -275
Capital Expenditures (CapEx)		 5.70 6.43 6.09 6.93 7.25 6.82 12 11 11 8.94 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.25 -17 -18 -26 -32 -57 -31 -31 -46 -54 -26
Debt-free Net Working Capital (DFNWC)		 961 953 940 915 891 855 842 924 918 908 905
Net Working Capital (NWC)		 961 953 940 915 891 855 842 924 360 350 346
Net Nonoperating Expense (NNE)		 9.35 7.22 11 14 8.71 11 9.70 9.87 8.11 22 7.81
Net Nonoperating Obligations (NNO)		 -406 -404 -392 -374 -355 -344 -304 -301 -309 -307 -275
Total Depreciation and Amortization (D&A)		 2.89 -0.58 -1.33 -2.35 -3.89 -4.54 -2.57 -4.00 -4.28 -3.57 -3.33
Debt-free, Cash-free Net Working Capital to Revenue		 -1.71% -3.19% -3.54% -5.11% -6.36% -11.20% -5.95% -5.67% -7.98% -8.90% -4.23%
Debt-free Net Working Capital to Revenue		 177.16% 177.14% 179.95% 180.32% 176.76% 167.92% 160.27% 167.95% 158.83% 150.09% 145.56%
Net Working Capital to Revenue		 177.16% 177.14% 179.95% 180.32% 176.76% 167.92% 160.27% 167.95% 62.36% 57.86% 55.65%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.36) ($0.50) ($0.54) ($0.46) ($0.45) ($0.36) ($0.31) ($0.28) ($0.61) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 104.88M 104.66M 105.67M 106.29M 106.77M 106.39M 107.27M 107.70M 108.25M 107.83M 110.28M
Adjusted Diluted Earnings per Share		 ($0.25) ($0.36) ($0.50) ($0.54) ($0.46) ($0.45) ($0.36) ($0.31) ($0.28) ($0.61) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 104.88M 104.66M 105.67M 106.29M 106.77M 106.39M 107.27M 107.70M 108.25M 107.83M 110.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 104.95M 105.46M 106.21M 106.62M 106.86M 107.09M 107.61M 108.22M 108.20M 109.92M 111.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -30 -42 -44 -41 -36 -29 -24 -22 -44 -27
Normalized NOPAT Margin		 -13.15% -23.43% -34.52% -34.80% -32.02% -27.06% -20.98% -15.63% -14.48% -27.48% -17.10%
Pre Tax Income Margin		 -17.88% -25.35% -41.81% -42.76% -37.87% -28.80% -22.85% -15.12% -13.92% -34.23% -19.55%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About NovoCure's Financials

When does NovoCure's fiscal year end?

According to the most recent income statement we have on file, NovoCure's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has NovoCure's net income changed over the last 10 years?

NovoCure's net income appears to be on an upward trend, with a most recent value of -$168.63 million in 2024, rising from -$80.68 million in 2014. The previous period was -$207.04 million in 2023. Find out what analysts predict for NovoCure in the coming months.

What is NovoCure's operating income?
NovoCure's total operating income in 2024 was -$170.50 million, based on the following breakdown:
  • Total Gross Profit: $468.04 million
  • Total Operating Expenses: $638.54 million
How has NovoCure revenue changed over the last 10 years?

Over the last 10 years, NovoCure's total revenue changed from $15.49 million in 2014 to $605.22 million in 2024, a change of 3,807.2%.

How much debt does NovoCure have?

NovoCure's total liabilities were at $880.61 million at the end of 2024, a 12.4% increase from 2023, and a 4,302.8% increase since 2014.

How much cash does NovoCure have?

In the past 10 years, NovoCure's cash and equivalents has ranged from $57.61 million in 2014 to $240.82 million in 2023, and is currently $163.77 million as of their latest financial filing in 2024.

How has NovoCure's book value per share changed over the last 10 years?

Over the last 10 years, NovoCure's book value per share changed from 7.84 in 2014 to 3.33 in 2024, a change of -57.5%.


Related Companies

This page (NASDAQ:NVCR) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...
Stansberry Research | Sponsored
Trump to solve American wealth loss?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored